For how we live.
In PANKU-Lung01, 432 people with EGFR-mutated NSCLC that progressed on a third-generation EGFR tablet got izalontamab brengitecan or chemotherapy. Median progression-free survival was 11.1 versus 5.7 months.
In KEYNOTE-C93, 299 people with mismatch repair-deficient advanced endometrial cancer were randomised to pembrolizumab or to carboplatin plus paclitaxel. Median progression-free survival was 38.2 versus 8.4 months.
In HERON-Lung01, 498 people in China with EGFR-mutated NSCLC that had progressed after a targeted drug were randomised to ruzaltatug rezetecan or chemotherapy. Median progression-free survival was 8.3 versus 5.4 months.